---
layout: default
title: Nilotinib
parent: 僅模型預測 (L5)
nav_order: 99
evidence_level: L5
indication_count: 1
---

# Nilotinib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Nilotinib: Evaluation Report — Insufficient Data for Complete Assessment

## One-Sentence Summary

Nilotinib (DrugBank ID: DB04868) is currently under preliminary evaluation for drug repurposing potential.
However, **no TxGNN predicted indications were returned** in this Evidence Pack, and critical baseline data — including original indication, mechanism of action, and safety information — are all missing.
A complete evaluation cannot be conducted until blocking data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Predicted New Indication | No prediction available |
| TxGNN Prediction Score | No prediction available |
| Evidence Level | L5 (model prediction only — no results returned) |
| Taiwan Market Status | ✗ Not marketed (0 authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why a Complete Assessment Is Not Yet Possible

Currently, detailed mechanism of action data is not available for Nilotinib in this Evidence Pack. The `original_moa` field is missing, and no original approved indications have been recorded. Without these foundational elements, it is not possible to assess mechanistic plausibility for any proposed new indication.

More critically, the `predicted_indications` array returned zero results. This means TxGNN did not produce any candidate repurposing targets for Nilotinib under the current pipeline run. This may reflect a data pipeline issue, missing input features, or an intentional filtering threshold — the root cause should be diagnosed before proceeding.

Two blocking data gaps have been formally flagged in this Evidence Pack (DG001, DG002). Until these are remediated, the candidate cannot advance past initial triage.

---

## Clinical Trial Evidence

Currently no related clinical trials registered *(no predicted indication available to query against).*

---

## Literature Evidence

Currently no related literature available *(no predicted indication available to query against).*

---

## Taiwan Market Information

Nilotinib has **no approved licenses** in Taiwan as of the data cutoff (2026-04-20). There are no authorizations to display.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Key warnings, contraindications, and drug interaction data were not available in this Evidence Pack. The Taiwan package insert query returned a result (query log ID 4), but its contents were not parsed into the structured safety fields. DDI query returned no results.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack is incomplete in all dimensions critical to evaluation: no original indication, no MOA, no TxGNN predictions, and no structured safety data. No scoring or repurposing recommendation can be responsibly issued at this stage.

**To proceed, the following is needed:**

- **\[Blocking — DG001\]** Parse the Taiwan package insert PDF (query log ID 4 reports a successful fetch) to extract approved indications, key warnings, and contraindications and populate the `safety` fields
- **\[High — DG002\]** Retrieve Nilotinib's mechanism of action from DrugBank API (DB04868) and populate `drug.original_moa`
- **\[Critical\]** Diagnose why `predicted_indications` returned an empty array — check TxGNN pipeline input features, KG node coverage for DB04868, and prediction threshold settings
- Once predictions are available, re-run the Evidence Pack generation to populate clinical trial and literature evidence sections
- Confirm whether the absence of Taiwan market authorization affects the intended use case (if evaluation is for market entry, this is a separate regulatory track)
---

